DSM Pharmaceuticals: Hans Engels on Supply Chain Solutions and DSM's Sterile Facility

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: DSM Pharmaceuticals: Hans Engels on Supply Chain Solutions and DSM's Sterile Facility
Released on: July 21, 2010. © PharmaVentures Ltd
Share/save this page:
Follow us:
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks with Hans Engels, President and CEO of DSM Pharmaceuticals. Filmed at BioChicago 2010 in Chicago, USA, they discuss:

• Functions of DSM Pharmaceuticals

• Why pharmaceutical companies would consider using DSM's sterile facility

• DSM's perspective: A continual supply chain solutions provider

Functions of DSM Pharmaceuticals
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at BIO International Convention. On this show I have Hans Engels, who is President of DSM Pharmaceuticals , welcome to the show.
Hans Engels:
Thank you very much.
Fintan Walton:
Hans Engels, you are President of DSM Pharmaceuticals you've got a specific role a specific position within DSM Pharmaceuticals particularly at the end of the supply chain, could you describe what that function is?
Hans Engels:
We are receiving active pharmaceutical ingredients from other contract manufacturers or from our customers and convert this active pharmaceutical ingredients into the finished dose forms which can be liquid, sterile vials or freeze-dried sterile vials or tablets, capsules whatever.
Why would pharmaceutical companies consider using DSM 's sterile facility?
Fintan Walton:
Right so your capabilities are quite broad?
Hans Engels:
That's correct.
Fintan Walton:
So why would a pharmaceutical company ever want to consider using DSM for that specific capability?
Hans Engels:
The operation of a sterile facility is extremely expensive and requires high investment costs and there is a high degree of regulatory compliance necessary. So small and midsize biotech companies typically cannot afford or don't want to spend their money in this kind of operations, so they prefer to come to us.
DSM 's perspective:A continual supply chain solutions provider
Fintan Walton:
So from a DSM perspective how would you how do you visualize your service I mean across the whole supply chain? I know you fit towards the end of that supply chain the higher end of that supply chain, do you see yourselves as a continual supply chain solutions provider?
Hans Engels:
That's how we actually indeed how we see ourselves that we are playing a major role in the speed to market because the finishing step is that's not very intellectual property of the drug as really but it is extremely important to get a high quality product to the market. And typically what we see and what we saw is that the supply chain takes 90 days or something like that to get a product from the back stage into finished dose from which can get to the customer. We are able to cut this time down typically to something around 30 days and 30 days is almost the minimum you can get because you have all the sterility testing et cetera what you have to do which takes already 15 days and that's really where we see a large portion of the value we can create that we can do it that fast and the other portion of causes that we also maximize the amount of product which gets to the customer.
Fintan Walton:
Hans Engels, thank you very much indeed for coming on the show.
Hans Engels:
My pleasure. Thank you.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Hans Engels
Hans Engels .Ph.D.is President and Chief Executive Officer, DSM Pharmaceuticals , Inc. Hans Engels is responsible for all operations, marketing and sales for the pharma dosage forms manufacturing business. Prior to joining DSM in 1999, Hans Engels was the vice president of production and engineering for Alpha Therapeutics and has held various executive leadership positions for Bayer AG. Hans Engels holds a B.S. in Mechanical Engineering from the University of Dusseldorf in Germany, and an M.S. and Ph. D. in Chemical Engineering from the University of Aachen in Germany.
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
DSM Pharmaceuticals
DSM Pharmaceuticals Inc. is one of three business units within the DSM Pharmaceuticals Products business group. It is a global provider of finished dosage form manufacturing and related services to the pharmaceutical and biopharmaceutical markets providing broad capabilities in aseptic filling of liquid and freeze-dried cytotoxic and non-cytotoxic compounds, tablets, capsules, pharmaceutical development services, and clinical trial material manufacturing for solid and injectable forms. These services are centered at a single, technologically-advanced site in Greenville, North Carolina.